3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
6
Completed
4
Active not recruiting
4
Withdrawn
2
Unknown
1
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
27
Head & Neck
3
Gastrointestinal
3
Dermatologic
3
Tumor-Agnostic
2
Thoracic
2
Genitourinary
2
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
CNS
1
Conditions
Thyroid Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Paclitaxel
78
Carboplatin
72
Cisplatin
71
Bevacizumab
29
Radiotherapy
27
Brachytherapy
23
Hyperthermic Intraperitoneal Chemotherapy
20
Drug Therapy
20
olaparib
19
Gemcitabine
17
niraparib
16
apatinib
16
pembrolizumab
15
Surgical Procedures, Operative
15
liposomal doxorubicin
12
Cyclophosphamide
12
Surveys and Questionnaires
11
camrelizumab
10
Neoadjuvant Therapy
10
fludarabine
9
anlotinib
9
Taxes
9
Etoposide
9
Blood Specimen Collection
9
Topotecan
8
Docetaxel
8
Sentinel Lymph Node Biopsy
7
Platinum
7
Injections
7
Cytoreduction Surgical Procedures
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
palbociclib
×
Gynecologic
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled